The Working Group in Chronic Venous Disease (CVD) is a group of surgeons who are experts in venous disease, who have come together to discuss the role of venoactive therapies in the management of patients with Chronic Venous Disease (CVD).
Although these therapies are widely used outside the US with published clinical literature in support of their usage with specific patient populations, until recently, there were no such medications available in the US.
The purpose of the group’s meetings and discussion it to review the body of evidence on the pathophysiology of CVD and to discuss the role of venoactive therapies such as Micronized Purified Flavonoid Fracture (MPFF).
The Group is chaired by Dr. Ron Bush, and the participants are well known in the vascular community: Dr. Anthony Comerota, Dr. Mark Meissner, and Dr. Joseph Raffetto.
The Working Group in CVD is sponsored by Primus Pharmaceuticals, who are the manufacturers and distributors of a new formulation of MPFF, Diosmiplex (Vasculera) in the US.
Dr. Bush is one of the nation’s leading specialists in venous diseases. Dr. Bush founded and is the medical director for Vein Experts, a national group of venous specialists specializing in venous disease.
Dr. Comerota is Director of the Jobst Vascular Institute at ProMedica Toledo Hospital, Toledo, Ohio. Dr. Comerota has been a major contributor to the development of some of the newest forms of treatment for vascular disease.
Dr. Meissner is a Professor of Vascular Surgery at the University of Washington School of Medicine. He is past president of the American Venous Forum and a member of the board of directors of the American College of Phlebology.
Dr. Raffetto is an Associate Professor of Surgery at Harvard Medical School, Brigham and Women's Hospital and a vascular surgeon with research interest
in understanding the cellular mechanisms of vascular disease, particularly chronic venous insufficiency.